News
mRNA Cancer Vaccine Breakthrough: Moderna and Merck's Phase 3 Melanoma Trial Succeeds
Moderna and Merck announce Phase 3 trial success for personalized mRNA cancer vaccine intismeran, reducing melanoma recurrence risk by 50% and metasta...